title: HPV prevalence in Colombian women with cervical cancer: implications for vaccination in a developing country.
abstract: Human Papillomavirus (HPV) vaccines have been considered potentially cost-effective for the reduction of cervical cancer burden in developing countries; their effectiveness in a public health setting continues to be researched. We conducted an HPV prevalence survey among Colombian women with invasive cancer. Paraffin-embedded biopsies were obtained from one high-risk and one low-middle-risk regions. GP5+/GP6+ L1 primers, RLB assays, and E7 type specific PCR were used for HPV-DNA detection. 217 cases were analyzed with 97.7% HPV detection rate. HPV-16/18 prevalence was 63.1%; HPV-18 had lower occurrence in the high-risk population (13.8% versus 9.6%) allowing for the participation of less common HPV types; HPV-45 was present mainly in women under 50 and age-specific HPV type prevalence revealed significant differences. Multiple high-risk infections appeared in 16.6% of cases and represent a chance of replacement. Age-specific HPV prevalence and multiple high-risk infections might influence vaccine impact. Both factors highlight the role of HPVs other than 16/18, which should be considered in cost-effectiveness analyses for potential vaccine impact.
authors.affiliation: Subdirección Investigaciones, Instituto Nacional de Cancerología de Colombia, Bogota, Colombia. raulhmurillo@yahoo.com
authors.forename: Raúl
authors.initials: R
authors.lastname: Murillo
authors.forename: Mónica
authors.initials: M
authors.lastname: Molano
authors.forename: Gilberto
authors.initials: G
authors.lastname: Martínez
authors.forename: Juan-Carlos
authors.initials: JC
authors.lastname: Mejía
authors.forename: Oscar
authors.initials: O
authors.lastname: Gamboa
mesh_terms: D000328:Adult; D000368:Aged; D016009:Chi-Square Distribution; D003105:Colombia; D003430:Cross-Sectional Studies; D005260:Female; D052162:Human papillomavirus 16 / Q000235:genetics / Q000276:immunology*; D052161:Human papillomavirus 18 / Q000235:genetics / Q000276:immunology*; D006801:Humans; D008875:Middle Aged; D030361:Papillomavirus Infections / Q000453:epidemiology* / Q000517:prevention & control / Q000821:virology; D053918:Papillomavirus Vaccines / Q000008:administration & dosage*; D015995:Prevalence; D018709:Statistics, Nonparametric; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control / Q000821:virology
chemical_list: D053918:Papillomavirus Vaccines